FDA approves Novo Nordisk’s oral Type 2 diabetes drug
The drug, Rybelsus, is the first oral medication in the GLP-1 receptor agonist class. The approval was based on data from 10 trials that enrolled more than 9,500 patients.
The drug, Rybelsus, is the first oral medication in the GLP-1 receptor agonist class. The approval was based on data from 10 trials that enrolled more than 9,500 patients.